DK2097078T3 - Nanopartikler af paclitaxel og albumin i kombination med bevacizumab mod kræft - Google Patents

Nanopartikler af paclitaxel og albumin i kombination med bevacizumab mod kræft

Info

Publication number: DK2097078T3
Authority: DK; Denmark
Prior art keywords: paclitaxel; combination; against cancer; albumin nanoparticles; bevacizumab
Prior art date: 2006-11-06

Application number

DK07839976.3T

Other languages

English (en)

Inventor

Neil P Desai

Patrick Soon-Shiong

Original Assignee

Abraxis Bioscience Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-06

Filing date

2007-11-06

Publication date

2014-05-12

2007-11-06 Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc

2014-05-12 Application granted granted Critical

2014-05-12 Publication of DK2097078T3 publication Critical patent/DK2097078T3/da

Links

102000009027 Albumins Human genes 0.000 title 1
108010088751 Albumins Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
229930012538 Paclitaxel Natural products 0.000 title 1
229960000397 bevacizumab Drugs 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000002105 nanoparticle Substances 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK07839976.3T 2006-11-06 2007-11-06 Nanopartikler af paclitaxel og albumin i kombination med bevacizumab mod kræft DK2097078T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11/594,417 US20070166388A1 (en)	2005-02-18	2006-11-06	Combinations and modes of administration of therapeutic agents and combination therapy
PCT/US2007/023446 WO2008057562A1 (en)	2006-11-06	2007-11-06	Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Publications (1)

Publication Number	Publication Date
DK2097078T3 true DK2097078T3 (da)	2014-05-12

Family

ID=39111840

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07839976.3T DK2097078T3 (da)	2006-11-06	2007-11-06	Nanopartikler af paclitaxel og albumin i kombination med bevacizumab mod kræft
DK12154995.0T DK2481405T3 (da)	2006-11-06	2007-11-06	Nanopartikler af paclitaxel og albumin i kombination med bevacizumab mod kræft

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK12154995.0T DK2481405T3 (da)	2006-11-06	2007-11-06	Nanopartikler af paclitaxel og albumin i kombination med bevacizumab mod kræft

Country Status (22)

Country	Link
US (1)	US20070166388A1 (da)
EP (3)	EP2481405B1 (da)
JP (3)	JP5931323B2 (da)
KR (4)	KR20090087906A (da)
CN (2)	CN104940929A (da)
AU (1)	AU2007317859B2 (da)
BR (1)	BRPI0718528A2 (da)
CA (1)	CA2668607A1 (da)
CY (2)	CY1115271T1 (da)
DK (2)	DK2097078T3 (da)
ES (2)	ES2576289T3 (da)
HU (1)	HUE028472T2 (da)
IL (2)	IL198576A (da)
MX (1)	MX2009004803A (da)
NO (1)	NO343908B1 (da)
NZ (1)	NZ576856A (da)
PL (2)	PL2097078T3 (da)
PT (2)	PT2097078E (da)
RU (2)	RU2009121568A (da)
SI (2)	SI2097078T1 (da)
WO (1)	WO2008057562A1 (da)
ZA (1)	ZA200903132B (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030133955A1 (en) *	1993-02-22	2003-07-17	American Bioscience, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) *	1993-02-22	1995-08-08	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070116761A1 (en) *	1993-02-22	2007-05-24	Desai Neil P	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8137684B2 (en)	1996-10-01	2012-03-20	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ES2435944T3 (es) *	1997-06-27	2013-12-26	Abraxis Bioscience, Llc	Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US8853260B2 (en) *	1997-06-27	2014-10-07	Abraxis Bioscience, Llc	Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP1585548B1 (en)	2002-12-09	2018-06-27	Abraxis BioScience, LLC	Compositions and methods of delivery of pharmacological agents
WO2006089290A1 (en) *	2005-02-18	2006-08-24	Abraxis Bioscience Inc..	Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US8034765B2 (en) *	2005-08-31	2011-10-11	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0615265A8 (pt)	2005-08-31	2018-03-06	Abraxis Bioscience Llc	composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8440625B2 (en) *	2006-06-26	2013-05-14	University Of British Columbia	Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
US20080280987A1 (en) *	2006-08-31	2008-11-13	Desai Neil P	Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP2089055A4 (en) *	2006-11-01	2011-02-02	George Mason Intellectual Prop	METHOD FOR THE DETECTION AND CONTROL OF CANCER
PT2117520T (pt)	2006-12-14	2018-12-04	Abraxis Bioscience Llc	Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
LT2481402T (lt) *	2007-03-07	2018-10-25	Abraxis Bioscience, Llc	Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) *	2007-05-03	2010-07-01	Desai Neil P	Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) *	2007-06-01	2013-10-10	Abraxis Bioscience, Llc	Methods and compositions for treating recurrent cancer
JP2010530872A (ja) *	2007-06-22	2010-09-16	サイドース・エルエルシー	Ｔｗｅｅｎ８０を含まないドセタキセル可溶化製剤
ITMI20080284A1 (it) *	2008-02-22	2009-08-23	Indena Spa	Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CA2721153C (en) *	2008-04-10	2018-10-02	Abraxis Bioscience, Llc	Compositions of hydrophobic taxane derivatives and uses thereof
WO2010003057A2 (en)	2008-07-03	2010-01-07	Mayo Foundation For Medical Education And Research	Treating cancer
EP2153821A1 (en) *	2008-08-06	2010-02-17	BioAlliance Pharma	Oral formulations of camptothecin derivatives
RU2555326C2 (ru) *	2009-01-16	2015-07-10	Риджел Фармасьютикалз, Инк.	ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА
BRPI1008955A2 (pt)	2009-03-13	2015-09-01	Abraxis Bioscience Llc	Terapia de combinação com derivados de tiocolchicina.
CN102460167B (zh)	2009-04-15	2015-07-22	阿布拉科斯生物科学有限公司	不含朊病毒的纳米颗粒组合物和方法
EP2451459B1 (en) *	2009-07-07	2017-11-22	Normoxys, Inc.	Method of reducing multi-drug resistance using inositol tripyrophosphate
US20110092579A1 (en) *	2009-10-19	2011-04-21	Scidose Llc	Solubilized formulation of docetaxel
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
US8912228B2 (en)	2009-10-19	2014-12-16	Scidose Llc	Docetaxel formulations with lipoic acid
US8541465B2 (en) *	2009-10-19	2013-09-24	Scidose, Llc	Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
TWI619509B (zh)	2010-02-23	2018-04-01	建南德克公司	治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合
CN104784121A (zh) *	2010-03-26	2015-07-22	阿布拉科斯生物科学有限公司	治疗肝细胞癌的方法
WO2011123393A1 (en)	2010-03-29	2011-10-06	Abraxis Bioscience, Llc	Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ602385A (en) *	2010-03-29	2014-08-29	Abraxis Bioscience Llc	Methods of treating cancer
KR20130088116A (ko)	2010-06-04	2013-08-07	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
MY166014A (en) *	2010-06-07	2018-05-21	Abraxis Bioscience Llc	Combination therapy methods for treating proliferative diseases
US20120121510A1 (en) *	2010-11-11	2012-05-17	Brem Rachel F	Localized therapy following breast cancer surgery
US20130323265A1 (en) *	2010-11-15	2013-12-05	Oncomed Pharmaceuticals, Inc.	Methods for treating cancer with dll4 antagonists
HRP20200793T1 (hr)	2011-05-09	2020-10-16	Mayo Foundation For Medical Education And Research	Liječenje raka
TW201700103A (zh)	2011-11-01	2017-01-01	西建公司	利用胞嘧啶核苷類似物之口服配方治療癌症的方法
WO2013085902A1 (en)	2011-12-05	2013-06-13	The University Of Texas M.D.	Combination therapy methods for treating an inflammatory breast cancer
PT2790675T (pt)	2011-12-14	2019-09-23	Abraxis Bioscience Llc	Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
SI2825558T1 (sl)	2012-03-13	2019-08-30	F. Hoffmann-La Roche Ag	Kombinirana terapija za zdravljenje raka jajčnikov
CA2917407C (en)	2012-10-01	2023-03-14	Mayo Foundation For Medical Education And Research	Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
US9149455B2 (en)	2012-11-09	2015-10-06	Abraxis Bioscience, Llc	Methods of treating melanoma
US9511046B2 (en)	2013-01-11	2016-12-06	Abraxis Bioscience, Llc	Methods of treating pancreatic cancer
NZ630239A (en) *	2013-02-11	2017-08-25	Abraxis Bioscience Llc	Methods of treating melanoma
ES2804323T3 (es)	2013-03-12	2021-02-05	Abraxis Bioscience Llc	Procedimientos de tratamiento de cáncer de pulmón
CA2903548A1 (en)	2013-03-14	2014-09-25	Abraxis Bioscience, Llc	Methods of treating bladder cancer
US10842969B2 (en)	2013-10-25	2020-11-24	Mercator Medsystems, Inc.	Systems and methods of treating malacia by local delivery of hydrogel to augment tissue
WO2015134543A1 (en) *	2014-03-05	2015-09-11	Sorrento Therapeutics, Inc.	Pharmacokinetically equivalent nanoparticle compositions
EP2924022A1 (en) *	2014-03-27	2015-09-30	INDENA S.p.A.	Amorphous form of a thiocolchicine derivative
CA2950926A1 (en)	2014-06-13	2015-12-17	Mayo Foundation For Medical Education And Research	Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
JP6600651B2 (ja)	2014-06-16	2019-10-30	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	骨髄腫の治療
US20150359810A1 (en)	2014-06-17	2015-12-17	Celgene Corporation	Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015018380A2 (en) *	2014-07-03	2015-02-12	Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd.	Therapeutic nanoparticles and the preparation methods thereof
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
ES2763318T3 (es) *	2014-10-06	2020-05-28	Mayo Found Medical Education & Res	Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
US10527604B1 (en)	2015-03-05	2020-01-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en)	2015-03-05	2020-07-07	Abraxis Bioscience, Llc	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
EP3313401B1 (en)	2015-06-29	2021-10-06	Abraxis BioScience, LLC	Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
WO2017031368A1 (en) *	2015-08-18	2017-02-23	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
WO2017176265A1 (en) *	2016-04-06	2017-10-12	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
CN105288639A (zh) *	2015-11-23	2016-02-03	中国药科大学	一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用
EP3399861A4 (en)	2016-01-07	2019-08-07	Mayo Foundation for Medical Education and Research	METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en)	2016-02-12	2022-06-07	Mayo Foundation For Medical Education And Research	Hematologic cancer treatments
EP3432926A4 (en)	2016-03-21	2019-11-20	Mayo Foundation for Medical Education and Research	METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
CA3018340A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
RU2019105550A (ru) *	2016-08-05	2020-09-07	Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч	Модифицированные комплексы с наночастицами антитело-альбумин для лечения злокачественного новообразования
WO2018038253A1 (ja) *	2016-08-26	2018-03-01	哲治奥野	微小ナノ化薬剤およびその利用
EP3506950A1 (en)	2016-09-01	2019-07-10	Mayo Foundation for Medical Education and Research	Methods and compositions for targeting t-cell cancers
JP7525999B2 (ja)	2016-09-01	2024-07-31	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
CN109843924A (zh)	2016-09-06	2019-06-04	梅约医学教育与研究基金会	治疗表达pd-l1的癌症的方法
RU2756892C2 (ru)	2016-09-06	2021-10-06	Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч	Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (en)	2016-09-06	2019-07-17	Vavotar Life Sciences LLC	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN106310291A (zh) *	2016-09-14	2017-01-11	东南大学	主动靶向抗肿瘤纳米药物及其制备方法和应用
PL3532059T3 (pl)	2016-10-27	2022-05-09	Celgene Quanticel Research, Inc.	Terapia skojarzona z zastosowaniem inhibitora białka bet
EP3532077A4 (en) *	2016-10-28	2020-06-10	Nant Holdings IP, LLC	Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
RU2020118594A (ru)	2017-11-06	2021-12-09	Рапт Терапьютикс, Инк.	Противораковые агенты
WO2019104042A1 (en) *	2017-11-21	2019-05-31	University Of Iowa Research Foundation	Synthetically lethal nanoparticles for treatment of cancers
CN111683657A (zh) *	2017-12-19	2020-09-18	阿布拉科斯生物科学有限公司	利用纳米颗粒mTOR抑制剂联合疗法治疗结肠癌的方法
US11524053B2 (en)	2018-01-26	2022-12-13	The Regents Of The University Of California	Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
IL277402B1 (en)	2018-03-20	2026-04-01	Abraxis Bioscience Llc	Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
KR20220106758A (ko)	2019-10-28	2022-07-29	아브락시스 바이오사이언스, 엘엘씨	알부민 및 라파마이신의 제약 조성물
AU2020393842A1 (en)	2019-11-25	2022-06-16	The Regents Of The University Of California	Long-acting VEGF inhibitors for intraocular neovascularization
KR102263606B1 (ko)	2020-02-11	2021-06-10	충북대학교 산학협력단	파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도
WO2026090323A1 (en)	2024-10-23	2026-04-30	Incyte Corporation	Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor and its use in the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5470571A (en)	1988-01-27	1995-11-28	The Wistar Institute	Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL98528A0 (en)	1990-06-21	1992-07-15	Merck & Co Inc	Pharmaceutical compositions containing hybrid for killing bladder cancer cells
SK281143B6 (sk)	1991-03-06	2000-12-11	Merck Patent Gesellschaft Mit Beschr�Nkter Haftung	Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) *	1993-02-22	2000-08-01	Vivorx Pharmaceuticals, Inc.	Methods and compositions useful for administration of chemotherapeutic agents
WO1995019171A1 (en)	1994-01-14	1995-07-20	Cell Therapeutics, Inc.	Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
IL132240A0 (en)	1997-04-07	2001-03-19	Genentech Inc	Anti-vegf antibodies
CN1125651C (zh)	1998-04-16	2003-10-29	欧维塔有限公司	新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物
CA2369740A1 (en)	1999-04-22	2000-11-02	American Biosciences, Inc.	Long term administration of pharmacologically active agents
ITMI20001107A1 (it) *	2000-05-18	2001-11-18	Acs Dobfar Spa	Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040143004A1 (en)	2002-02-26	2004-07-22	Joseph Fargnoli	Metronomic dosing of taxanes
EP1585548B1 (en)	2002-12-09	2018-06-27	Abraxis BioScience, LLC	Compositions and methods of delivery of pharmacological agents
NZ621449A (en) *	2003-05-30	2015-07-31	Genentech Inc	Treatment with anti-vegf antibodies
AR046510A1 (es) *	2003-07-25	2005-12-14	Regeneron Pharma	Composicion de un antagonista de vegf y un agente anti-proliferativo
US20080085902A1 (en) *	2003-09-23	2008-04-10	Guido Bold	Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
WO2006001911A2 (en)	2004-05-06	2006-01-05	Genentech, Inc.	Crystal structure of the hepatocyte growth factor beta chain and methods of use
MXPA06014065A (es)	2004-06-01	2007-01-31	Genentech Inc	Conjugados de droga-anticuerpo y metodos.
EP1753455A2 (en)	2004-06-04	2007-02-21	Genentech, Inc.	Method for treating multiple sclerosis
SV2006002143A (es)	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US8772269B2 (en) *	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US20080161251A1 (en) *	2005-01-21	2008-07-03	Astex Therapeutics Limited	Pharmaceutical Compounds
WO2006089290A1 (en) *	2005-02-18	2006-08-24	Abraxis Bioscience Inc..	Combinations and modes of administration of therapeutic agents and combination therapy
WO2006090928A1 (ja) *	2005-02-28	2006-08-31	Eisai R & D Management Co., Ltd.	スルホンアミド化合物の血管新生阻害物質との新規併用
BRPI0615265A8 (pt) *	2005-08-31	2018-03-06	Abraxis Bioscience Llc	composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) *	2005-08-31	2011-10-11	Abraxis Bioscience, Llc	Compositions and methods for preparation of poorly water soluble drugs with increased stability

2006
- 2006-11-06 US US11/594,417 patent/US20070166388A1/en not_active Abandoned
2007
- 2007-11-06 KR KR1020097011640A patent/KR20090087906A/ko not_active Ceased
- 2007-11-06 PT PT78399763T patent/PT2097078E/pt unknown
- 2007-11-06 CN CN201510264733.0A patent/CN104940929A/zh active Pending
- 2007-11-06 AU AU2007317859A patent/AU2007317859B2/en active Active
- 2007-11-06 JP JP2009536282A patent/JP5931323B2/ja active Active
- 2007-11-06 KR KR1020157014446A patent/KR20150065957A/ko not_active Ceased
- 2007-11-06 WO PCT/US2007/023446 patent/WO2008057562A1/en not_active Ceased
- 2007-11-06 ZA ZA200903132A patent/ZA200903132B/xx unknown
- 2007-11-06 HU HUE12154995A patent/HUE028472T2/en unknown
- 2007-11-06 SI SI200731475T patent/SI2097078T1/sl unknown
- 2007-11-06 ES ES12154995.0T patent/ES2576289T3/es active Active
- 2007-11-06 CA CA002668607A patent/CA2668607A1/en not_active Abandoned
- 2007-11-06 SI SI200731795A patent/SI2481405T1/sl unknown
- 2007-11-06 MX MX2009004803A patent/MX2009004803A/es active IP Right Grant
- 2007-11-06 PL PL07839976T patent/PL2097078T3/pl unknown
- 2007-11-06 ES ES07839976.3T patent/ES2469716T3/es active Active
- 2007-11-06 RU RU2009121568/15A patent/RU2009121568A/ru unknown
- 2007-11-06 EP EP12154995.0A patent/EP2481405B1/en active Active
- 2007-11-06 EP EP16161396.3A patent/EP3108885A1/en not_active Withdrawn
- 2007-11-06 DK DK07839976.3T patent/DK2097078T3/da active
- 2007-11-06 DK DK12154995.0T patent/DK2481405T3/da active
- 2007-11-06 BR BRPI0718528-6A patent/BRPI0718528A2/pt not_active Application Discontinuation
- 2007-11-06 KR KR1020177002657A patent/KR101857142B1/ko active Active
- 2007-11-06 PL PL12154995.0T patent/PL2481405T3/pl unknown
- 2007-11-06 NZ NZ576856A patent/NZ576856A/en not_active Application Discontinuation
- 2007-11-06 PT PT121549950T patent/PT2481405E/pt unknown
- 2007-11-06 CN CNA2007800490545A patent/CN101573108A/zh active Pending
- 2007-11-06 KR KR1020187002044A patent/KR20180012339A/ko not_active Withdrawn
- 2007-11-06 EP EP07839976.3A patent/EP2097078B1/en active Active
2009
- 2009-05-05 IL IL198576A patent/IL198576A/en active IP Right Grant
- 2009-06-05 NO NO20092179A patent/NO343908B1/no unknown
2013
- 2013-11-05 RU RU2013149282A patent/RU2673805C2/ru active
- 2013-11-07 JP JP2013230872A patent/JP2014043454A/ja not_active Withdrawn
2014
- 2014-06-26 CY CY20141100462T patent/CY1115271T1/el unknown
2015
- 2015-10-23 JP JP2015208557A patent/JP2016014073A/ja active Pending
2016
- 2016-03-02 IL IL244390A patent/IL244390A/en active IP Right Grant
- 2016-06-17 CY CY20161100552T patent/CY1117725T1/el unknown

Also Published As

Publication number	Publication date
IL244390A (en)	2017-04-30
US20070166388A1 (en)	2007-07-19
HK1173976A1 (en)	2013-05-31
EP2097078B1 (en)	2014-04-16
PL2481405T3 (pl)	2016-09-30
EP2481405B1 (en)	2016-03-23
KR20090087906A (ko)	2009-08-18
KR101857142B1 (ko)	2018-05-14
EP3108885A1 (en)	2016-12-28
RU2673805C2 (ru)	2018-11-30
EP2097078A1 (en)	2009-09-09
RU2009121568A (ru)	2010-12-20
ES2576289T3 (es)	2016-07-06
IL198576A (en)	2016-12-29
ZA200903132B (en)	2010-08-25
ES2469716T3 (es)	2014-06-18
PT2097078E (pt)	2014-07-25
HUE028472T2 (en)	2016-12-28
RU2013149282A (ru)	2015-05-10
CN101573108A (zh)	2009-11-04
KR20180012339A (ko)	2018-02-05
CY1117725T1 (el)	2017-05-17
KR20150065957A (ko)	2015-06-15
WO2008057562A1 (en)	2008-05-15
JP5931323B2 (ja)	2016-06-08
JP2014043454A (ja)	2014-03-13
IL244390A0 (en)	2016-04-21
CN104940929A (zh)	2015-09-30
CA2668607A1 (en)	2008-05-15
PL2097078T3 (pl)	2014-09-30
NO343908B1 (no)	2019-07-01
JP2016014073A (ja)	2016-01-28
KR20170016017A (ko)	2017-02-10
NO20092179L (no)	2009-08-06
IL198576A0 (en)	2010-02-17
PT2481405E (pt)	2016-06-08
SI2481405T1 (sl)	2016-08-31
CY1115271T1 (el)	2017-01-04
MX2009004803A (es)	2009-07-09
AU2007317859A1 (en)	2008-05-15
JP2010509331A (ja)	2010-03-25
BRPI0718528A2 (pt)	2013-11-19
EP2481405A1 (en)	2012-08-01
AU2007317859B2 (en)	2013-07-25
NZ576856A (en)	2012-06-29
DK2481405T3 (da)	2016-06-06
SI2097078T1 (sl)	2014-07-31

Publication	Publication Date	Title
IL244390A0 (en)	2016-04-21	Nonparticles of paclitaxel and albumin in combination with bevacizumab against cancer
EP2054843A4 (en)	2012-12-12	REDUCTION OF NOISE IN DIGITAL IMAGES
BRPI0819573A2 (pt)	2015-05-05	Composição e artigo
BRPI0807908A2 (pt)	2014-06-17	Melhoramentos em composições medicinais.
DE112006001565A5 (de)	2008-03-27	Nanopartikel-Wirkstoff-Konjugate
DK2063907T3 (da)	2017-11-13	Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
PL3053933T3 (pl)	2018-03-30	Warianty pochodzące z actriib i ich zastosowania
BRPI0717339A2 (pt)	2013-10-15	Reversor de empuxo e nacela de turboélice
SI2046324T1 (sl)	2017-06-30	Zdravljenje in preventiva mukozitisa z derivati antocianidina
DK2127652T3 (da)	2013-06-10	Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination
SI2185552T1 (sl)	2014-07-31	Dipeptoidna predzdravila in njihova uporaba
EP2170222A4 (en)	2013-07-10	MEDICAL IMPLANT WITH CERAMIC LAYER
BRPI0822914A2 (pt)	2015-06-23	Composição, filme e métodos relacionados
EP2224093A4 (en)	2012-08-29	COMPRESSOR WITH INTEGRATED REGULATOR
DK2280734T3 (da)	2014-05-26	Faktor-ix-konjugater med forlængede halveringstider
DK2235002T3 (da)	2013-03-11	4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
EP2243261A4 (en)	2011-03-02	TRANSPARENT BYPASS AND ASSOCIATED MECHANISMS
BRPI0816789A2 (pt)	2015-03-17	Goji e inflamação
DK2101805T3 (da)	2013-01-21	Integrinligander til anvendelse i behandling af cancer
DK2234968T3 (da)	2013-06-17	(aza)indolderivat substitueret i position 5, farmaceutisk sammensætning omfattende det, mellemliggende forbindelser og fremstillingsproces dertil
DK2004183T3 (da)	2013-09-23	Mazindol-kombination i behandlingen af opmærksomhedsunderskud/hyperaktivitet
EP2315600A4 (en)	2012-11-28	COMPOSITIONS AND METHODS RELATING TO SIRT1 FUNCTION
DK2235021T3 (da)	2012-10-08	Epoxyguainderivater og behandling af cancer
BRPI0910187A2 (pt)	2016-01-19	película e artigo
EP2224094A4 (en)	2012-08-29	COMPRESSOR WITH INTEGRATED REGULATOR